AZ'6421

• Description :

  AZ'6421 acts as Protcolysis Targeting Chimera (PROTAC) to selectively degrade estrogen receptor alpha. AZ'6421 has a potent anti-tumour effect to inhibit the uncontrolled cellular proliferation which arises from malignant disease. AZ'6421 can be used for the research of cancer such as breast cancer[1].

• UNSPSC :

  12352005

• Target :

  Estrogen Receptor/ERR; PROTACs

• Type :

  Reference compound

• Related Pathways :

  PROTAC; Vitamin D Related/Nuclear Receptor

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/az-6421.html

• Purity :

  98.13

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  C[C@@H](N1CC(C)(F)C)CC2=C(NC3=C2C=CC=C3)[C@H]1C4=C(F)C=C(OCCCOCCCOCC(N[C@@H](C(C)(C)C)C(N5[C@H](C(NCC6=CC=C(C7=C(C)N=CS7)C=C6)=O)C[C@@H](O)C5)=O)=O)C=C4F

• Molecular Formula :

  C52H65F3N6O7S

• Molecular Weight :

  975.17

• References & Citations :

  [1]Bin Yang, et al. Compounds and their use in treating cancer. Patent WO2019123367A1.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2361115-35-5]